Just very briefly, what we said was that we are voluntarily collaborating internationally, and absolutely with generics, and that has proven to be far more effective. That partnership is the solution, but it's voluntary. We're very proud of the donations we make and we've made them on a voluntary basis. But never did we suggest that's enough.
I was trying to make the point that CAMR is limited and goes only so far. What we thankfully have been seeing—and I hope we can continue to work with everybody on this—is that if we push the voluntary collaboration, not for donations but for partnerships, we can go much further and respond to it, and I actually think we all unanimously agree on this issue.